MODERATE TO SEVERE GLABELLAR LINES
Clinical trials for MODERATE TO SEVERE GLABELLAR LINES explained in plain language.
Never miss a new study
Get alerted when new MODERATE TO SEVERE GLABELLAR LINES trials appear
Sign up with your email to follow new studies for MODERATE TO SEVERE GLABELLAR LINES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New botulinum toxin aims to smooth frown lines in phase 2 trial
Symptom relief CompletedThis study tests a new injection called YY003, a recombinant botulinum neurotoxin type A, for treating moderate to severe frown lines between the eyebrows (glabellar lines) in adults. Participants receive a single set of small injections into five points between the brows. The tr…
Matched conditions: MODERATE TO SEVERE GLABELLAR LINES
Phase: PHASE2 • Sponsor: Chongqing Claruvis Pharmaceutical Co., Ltd. • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
New Botox-Like injection aims to smooth frown lines safely
Symptom relief CompletedThis study tests a new form of botulinum toxin (YY001) for treating moderate to severe frown lines between the eyebrows. About 488 adults aged 18 to 65 will receive repeated injections over time. Researchers will monitor safety, side effects, and how well the treatment works to r…
Matched conditions: MODERATE TO SEVERE GLABELLAR LINES
Phase: PHASE3 • Sponsor: Chongqing Claruvis Pharmaceutical Co., Ltd. • Aim: Symptom relief
Last updated Jul 01, 2026 00:00 UTC
-
New wrinkle treatment AGN-151586 tested in japanese adults
Symptom relief CompletedThis early-stage trial tested an investigational botulinum toxin injection called AGN-151586 for moderate to severe frown lines (glabellar lines) in 24 Japanese adults. Participants received either the active drug or a placebo, and researchers measured wrinkle improvement and saf…
Matched conditions: MODERATE TO SEVERE GLABELLAR LINES
Phase: PHASE1 • Sponsor: AbbVie • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC